Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ArriVent BioPharma, Inc. (AVBP)

ArriVent reports 44.8% ORR for ARR-217 in late-line colorectal cancer Phase 1 data

Positive Impact 3 of 5 other Written later

ArriVent BioPharma reported initial Phase 1 data for its cadherin-17-targeted antibody-drug conjugate ARR-217 at the ESMO Congress 2026, based on 123 patients treated as of an August 5, 2026 data cutoff. The company said the drug was generally well tolerated and has advanced ARR-217 into a Phase 1b dose optimization study, with further data expected in 2027. The results are early and come from an open-label study, and the filing reports a notable rate of Grade 3 or higher treatment-related adverse events.

Key points

  • At the 6 mg/kg Q3W dose, the objective response rate was 44.8% (13/29) and the disease control rate was 93.1% (27/29) in pre-treated colorectal cancer patients.
  • Across all doses, 30.1% (37/123) of patients had Grade 3 or higher treatment-related adverse events, including neutropenia (12.2%) and diarrhea (8.9%).
  • ARR-217 has advanced into Phase 1b dose optimization at 5 and 6 mg/kg Q3W, with further dose optimization data expected in 2027.
  • ArriVent will host a virtual webinar on Monday, October 26, 2026, at 8 am ET.

The filing

CompanyArriVent BioPharma, Inc. (AVBP)
Form8-K, current report
Filed with the SECOct 26, 2026, 6:00 AM ET
Accession number0001104659-26-118550

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.